GlassScriptPhysician profile
Heather Black
NPI 1851717573
$2,001.88
in general payments reported to CMS, 2019-2025
22 companies · $643 in 2025
The $643 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $56.36 · 2022: $70.54 · 2023: $417 · 2024: $814 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,874.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $335.45 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $216.23 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $209.65 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $203.48 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $166.23 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbott Laboratories | $128.20 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $124.26 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $110.21 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| Dexcom, INC. | $103.84 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $98.70 | 2023-2025 | |
| Eisai INC. | $56.36 | 2021 | |
| Phathom Pharmaceuticals, INC. | $39.05 | 2024-2025 | Voquezna |
| Mylan Specialty L.P. | $37.96 | 2024 | Yupelri |
| Exact Sciences Corporation | $28.67 | 2023-2024 | Cologuard Collection Kit |
| Viatris Specialty LLC | $26.47 | 2025 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $23.97 | 2024 | Heplisav-B |
| Corcept Therapeutics | $17.72 | 2024 | Korlym |
| Astellas Pharma US INC | $17.38 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $16.72 | 2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $14.00 | 2025 | Zoryve |
| Neos Therapeutics, LP | $13.69 | 2023 | Cotempla Xr-Odt |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Black listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.